Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)

Lignende værker

• Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial
  af: Jones, D, et al.
  Udgivet: (2019)
• Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
  af: Mehanna, H, et al.
  Udgivet: (2019)
• Sensitive HPV detection in oropharyngeal cancers
  af: Winder, D.M., et al.
  Udgivet: (2009)
• Clinico-pathological features of oropharyngeal squamous cell carcinomas in Malaysia with reference to HPV infection
  af: Yap, Lee Fah, et al.
  Udgivet: (2018)
• Therapeutic HPV vaccines
  af: Hancock, G, et al.
  Udgivet: (2017)